Compare SFBC & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFBC | RNTX |
|---|---|---|
| Founded | 1953 | 2001 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.8M | 89.0M |
| IPO Year | 2012 | N/A |
| Metric | SFBC | RNTX |
|---|---|---|
| Price | $43.74 | $0.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 13.6K | ★ 614.2K |
| Earning Date | 04-28-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | ★ 53.89 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $72.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.68 | $0.85 |
| 52 Week High | $48.85 | $2.18 |
| Indicator | SFBC | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 46.29 |
| Support Level | $43.72 | $0.85 |
| Resistance Level | $44.42 | $1.32 |
| Average True Range (ATR) | 1.28 | 0.08 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 70.71 | 59.03 |
Sound Financial Bancorp Inc operates as the holding company for Sound Community Bank that provides traditional banking and other financial services for individuals and businesses. It attracts retail and commercial deposits from the public and invests those funds, along with borrowed funds, in loans secured by first and second mortgages on one-to-four-family residences including home equity loans and lines of credit, commercial and multifamily real estate, construction and land, consumer and commercial business loans. The bank also offers secured and unsecured consumer loan products, including manufactured home loans, floating home loans, automobile loans, boat loans, and recreational vehicle loans.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.